Oral thin films

Patent metadata

Field	Value
Publication number	US-12539280-B2
Application number	US-201917311153-A
Country	US
Kind code	B2
Filing date	Dec 6, 2019
Priority date	Dec 7, 2018
Publication date	Feb 3, 2026
Grant date	Feb 3, 2026

Abstract

An orally dissolvable film includes at least one layer comprising a first pharmaceutically active ingredient; a resinate comprising an ion exchange resin and a second pharmaceutically active ingredient; and a matrix and/or binder. The provision of a first pharmaceutically active ingredient, e.g., dispersed or dissolved in the film, and of a resinate comprising an ion exchange resin and a second pharmaceutically active ingredient, may allow immediate release of the first active ingredient, and controlled, sustained and/or delayed release of the second active ingredient.

First claim

The invention claimed is:

1 . An orally dissolvable film including at least one layer, wherein a first layer of the at least one layer comprises a non-complexed first pharmaceutically active ingredient that provides an immediate release rate: said first layer of said at least one layer further comprising a resinate comprising an ion exchange resin that provides a controlled and/or delayed release rate for a second pharmaceutically active ingredient, and a matrix and/or binder, wherein the immediate release rate is selected from the group consisting of at least a 30% release of said first pharmaceutically active ingredient and at least a 50% release of said first pharmaceutically active ingredient, during the first 5 minutes, when measured at pH 6.8, and wherein the controlled and/or delayed release rate is selected from the group consisting of about a 5-80% release of the second pharmaceutically active ingredient and about a 10-60% release of the second pharmaceutically active ingredient, after 1 hour, when measured at pH 6.8.

2 . The film according to claim 1 , wherein the first pharmaceutically active ingredient and/or the resinate is incorporated within the layer of the film.

3 . The film according to claim 1 , wherein the first pharmaceutically active ingredient is provided in the layer in an amount of about 0.1-50 wt. % based upon the total weight of the film.

4 . The film according to claim 1 , wherein the resinate is provided in the one layer in an amount of about 1-50 wt. % based upon the total weight of the film.

5 . The film according to claim 1 , wherein the weight ratio of the second pharmaceutically active ingredient to the ion exchange resin in the resinate is about 2:1 to 1:5.

6 . The film according to claim 1 , wherein the immediate release rate is selected from the group consisting of at least a 50% release of the first pharmaceutically active ingredient and at least a 60% release of said first pharmaceutically active ingredient, during the first 5 minutes, when measured at pH 1.2.

7 . The film according to claim 1 , wherein the controlled and/or delayed release rate is selected from the group consisting of about a 10-80% release of the second pharmaceutically active ingredient and about a 20-60% release of the second pharmaceutically active ingredient, after 1 hour, when measured at pH 1.2.

8 . The film according to claim 1 , wherein the ion exchange resin is provided in the form of beads having an associated particle size and/or or associated mesh size, the mesh size and/or particle size of the ion exchange resin or a mixture of ion exchange resins being selected to provide a desired rate of release of the active ingredient or drug.

9 . The film according to claim 8 , wherein the associated mesh size is in the region of 50-100 mesh- and/or the associated particle size is in the region of 150-300 μm.

10 . The film according to claim 8 , wherein the associated mesh size is in the region of 100-200 mesh and/or the associated particle size is in the region of 74-150 μm.

11 . The film according to claim 8 , wherein the associated mesh size is in the region of 200-400 mesh and/or the associated particle size is in the region of 37-74 μm.

12 . The film according to claim 1 , wherein the ion-exchange resin and/or resinate is provided in the form of particles coated and/or encapsulated within a processing material selected so as to withstand degradation or dissolution within one or more areas of the digestive system, and degrade or dissolve in one or more other areas of the digestive system.

13 . The film according to claim 1 , wherein the ion exchange resin comprises a free or unloaded ion exchange resin.

14 . The film of claim 1 , wherein the first pharmaceutically active ingredient and the second pharmaceutically active ingredient are the same.

15 . The film of claim 1 , wherein the first pharmaceutically active ingredient and the second pharmaceutically active ingredient are different.

16 . The film according to claim 1 , wherein said film is prepared by casting on a support.

17 . The film according to claim 1 , wherein said first pharmaceutically active ingredient is applied to the surface of the layer.

18 . The film according to claim 2 , wherein said incorporated first pharmaceutically active ingredient is absorbed, dispersed or dissolved within the layer.

19 . The film according to claim 17 , wherein said applied first pharmaceutically active ingredient is imprinted, coated or spread on the surface of the layer.

Assignees

• Univ Strathclyde

Inventors

• Mullen Alexander Balfour

Classifications

• A61K33/42

  Phosphorus; Compounds thereof · CPC title

• A61K31/485

  Morphinan derivatives, e.g. morphine, codeine · CPC title

• A61K31/4045

  Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin · CPC title

• A61K31/196

  the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title

• A61K31/166

  having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol · CPC title